Results 91 to 100 of about 11,226 (207)

Daratumumab bewährt sich in der Rezidivtherapie

, 2018
Die aktualisierte Auswertung der Phase-III-Studie POLLUX untermauert den anhalten-den Benefit von Daratumumab zusätzlich zu Lenalidomid/Dexamethason (Rd) bei Patientien mit rezidiviertem oder refraktärem MM (rrMM): Durch die Daratumumab-Addition werden ...
Katharina Arnheim
core   +1 more source

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

OncoImmunology, 2019
Daratumumab is an anti-CD38 fully human IgG1 mAb approved for multiple myeloma treatment. One of the proposed mechanisms of action is the induction of antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells.
Maria C. Ochoa, Elisabeth Perez-Ruiz, Luna Minute, Carmen Oñate, Guiomar Perez, Inmaculada Rodriguez, Aintzane Zabaleta, Diego Alignani, Myriam Fernandez-Sendin, Ascension Lopez, Aura Muntasell, Miguel F. Sanmamed, Bruno Paiva, Miguel Lopez-Botet, Pedro Berraondo, Ignacio Melero   +15 more
doaj   +1 more source

Clinical implications of imlifidase interference in antibody screening and transfusion management

Transfusion, EarlyView.
Abstract Background Imlifidase has received conditional approval from the EMA for desensitizing deceased donor kidney transplant recipients. It works by cleaving IgG into F(ab′)2 and Fc fragments, thereby reducing the risk of antibody‐mediated rejection. However, its impact on diagnostic assays remains understudied. Case Report We present the case of a
Zgjim Osmani, Aiko P. J. de Vries, Arjan Albersen   +2 more
wiley   +1 more source

Retreatment with talquetamab and pomalidomide in triple‐class–BCMA–GPRC5D refractory myeloma

British Journal of Haematology, EarlyView.
Kian J. Rahbari, Gliceida M. Galarza Fortuna, Bhagirathbhai Dholaria, Douglas W. Sborov, Muhamed Baljevic   +4 more
wiley   +1 more source

International multicentre evaluation of a new anti‐idiotypic anti‐daratumumab for resolving pre‐transfusion interferences

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Daratumumab, a therapeutic human anti‐CD38 monoclonal antibody, improves multiple myeloma outcomes but interferes with pre‐transfusion testing by binding CD38 on reagent red blood cells (RBCs), potentially masking clinically significant alloantibodies.
Arnaud Reggiani, Sofia Lejon Crottet, Sophie Waldvogel, Charlotte Engström, Serelina Coluzzi, Antonella Matteocci, Janis R. Hamilton, Levent Tufan Kumas, Karen M. K. de Vooght, Jill R. Storry, Jennylyn Flores, Núria Nogués, Carlos Cotorruelo, Molly Rutherford, Eveline B. Nilsen, Monika Pelc‐Kłopotowska, Jolanta Korzeniowska, Alessandra Baffa, Inna Sareneva, Nor Hafizah Ahmad, Katarzyna Szczudlo, Athif Rahman, Laser Sanal, Lise Jørgensen, Karolina Majewska Rochowiak, Monika Salwierz, Elisaveta Grancharova, Bojana Zivkovic, Jessica Alvarez, Mareike Riedl, Achim Knappik   +30 more
wiley   +1 more source

Response to daratumumab-retreatment in patients with multiple myeloma

Daratumumab is an effective therapy in multiple myeloma (MM). We assessed whether daratumumab retreatment may re-induce significant responses and which patients do benefit the most.
Ihorst, Gabriele, Greil, Christine, Engelhardt, Monika, Wäsch, Ralph, Souren, Laura   +4 more
core   +1 more source

Plasmacytic markers as immunotherapeutic targets for primary CD20‐negative aggressive B‐cell lymphomas

British Journal of Haematology, EarlyView.
Frank Neumann, Claudia Schormann, Onur Cetin, Igor A. Kos, Moritz Bewarder, Eva C. Schwarz, Stefan Lohse, Stephanie Maurer, Philipp B. Staber, Joerg T. Bittenbring, Sigrun Smola, Konstantinos Christofyllakis, Markus Hoth, Lorenz Thurner   +13 more
wiley   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

American Journal of Hematology, Volume 101, Issue 7, Page 1433-1439, July 2026.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz, Winfried Alsdorf, Lisa Leypoldt, Piet Sonnemann, Christoph Schaefers, Jule Artzenroth, Marie Harzer, Abdulaziz Kamili, Leandra Bartke, Leon Cords, Jan Vorwerk, Theo Leitner, Markus Maulhardt, Kerstin Brinkert, Annamaria Brioli, Tim Richardson, Udo Holtick, Stefan M. Hillmann, Hans Salwender, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Ricardo Kosch   +22 more
wiley   +1 more source

Cost‐effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma

British Journal of Haematology, EarlyView.
Sohaib Irfan, M. Abdullah Jamil, Muhammad Bilal Abid   +2 more
wiley   +1 more source